Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Vericiguat, Standard of Care Group.
- Who it may be relevant to
- Registry conditions: Cardio Vascular Disease, Cardiopulmonary Bypass. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
Overview
The purpose of this study is to evaluate the efficacy and safety of perioperative vericiguat in patients undergoing cardiovascular surgery. Patients at high risk of heart failure or with confirmed cardiac dysfunction will be randomly assigned to receive either vericiguat plus standard of care or standard of care alone. The primary objective is to determine whether perioperative administration of vericiguat can reduce (I) the Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury; (II) Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI), and the incidence of Major Adverse Cardiovascular Events (MACE) within 12 months after surgery.
Detailed description
Perioperative pathophysiological changes in cardiovascular surgery, such as stress response, ischemia-reperfusion injury, and endothelial dysfunction, often lead to an increased risk of postoperative complications, especially postoperative heart failure and ventricular remodeling. This study hypothesizes that vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, can improve endothelial function and reduce postoperative cardiovascular complications by repairing the impaired NO-sGC-cGMP signaling pathway. This is a multicenter, randomized, parallel-group, controlled trial. A total of 600 eligible patients will be randomized in a 1:1 ratio. The experimental group will receive oral vericiguat (starting at 2.5 mg once daily 3 days before surgery, and up-titrated to a target dose of 10 mg once daily postoperatively) in addition to standard perioperative care for 6 months. The control group will receive standard perioperative care alone.
Interventions
- Drug Vericiguat
Patients will receive oral vericiguat in addition to standardized perioperative care. Vericiguat will be initiated 3 days before surgery at a dose of 2.5 mg once daily. Postoperatively, upon resumption of enteral nutrition, vericiguat will be continued and gradually up-titrated every 2 weeks based on blood pressure tolerability to 5 mg, and then to a target dose of 10 mg once daily, taken with food, for a total duration of 1 months. - Drug Standard of Care Group
Patients will receive standardized perioperative cardiovascular surgery care alone, without vericiguat or placebo. Standard care includes preoperative preparation, postoperative monitoring, anti-infection, antiplatelet/anticoagulation, diuretics, beta-blockers, SGLT2 inhibitors, and other symptomatic treatments for heart failure according to current guidelines.
Primary outcome measures
- Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury [Time frame: Up to 7 days postoperatively (or until ICU discharge, whichever comes first).]
- Incidence of Major Adverse Cardiovascular Events (MACE) [Time frame: Up to 6 months postoperatively]
- Incidence of Major Sterile Inflammation-Related Organ Injuries (MSIRI) [Time frame: Up to 7 days postoperatively.]
- Maximum Sequential Organ Failure Assessment (SOFA) Score [Time frame: Up to 7 days postoperatively.]
Eligibility criteria
Inclusion criteria
- Aged 18 to 80 years, any sex;
- Scheduled to undergo cardiovascular surgery at the study centers, including coronary artery bypass grafting (CABG), heart valve replacement/repair, and great vessel surgery;
- Preoperative evaluation indicates a high risk of heart failure or confirmed cardiac dysfunction;
- Systolic blood pressure (SBP) >= 100 mmHg;
- Expected to complete the 6-month postoperative follow-up;
- Signed written informed consent by the patient or their authorized representative.
Exclusion criteria
- Current use of other sGC stimulators or phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil);
- Severe hypotension (symptomatic hypotension or resting SBP < 90 mmHg);
- Severe hepatic or renal dysfunction (Hepatic: Child-Pugh class C, or ALT/AST > 3 times the upper limit of normal; Renal: eGFR < 15 mL/min/1.73m\^2, or requiring chronic dialysis);
- Malignant tumors, severe hematological diseases, or severe malnutrition (albumin < 25 g/L);
- Known allergy to vericiguat or placebo components;
- Pregnant or lactating women, or those planning to become pregnant during the study period;
- Currently participating in other interventional clinical trials;
- Moderate to severe cognitive impairment without a fixed guardian, unable to cooperate with treatment and follow-up;
- Confirmed severe infection, sepsis, or septic shock preoperatively.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
China · 1 center
- The First Affiliated Hospital of Nanjing Medical University — Nanjing
Identifiers
NCT: NCT07594509 · PANDA XIII